IMUNON says data monitoring committee backs continuing Phase 3 OVATION 3 ovarian cancer trial unchanged

Imunon, Inc.

Imunon, Inc.

IMNN

0.00
  • Imunon’s independent monitoring committee recommended continuing the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.
  • No new efficacy results were presented; the decision followed a safety and trial-conduct review with no changes to the study.
  • The study targets overall survival as the primary endpoint, with interim looks intended to support a faster FDA filing if results are positive.
  • Enrollment reached 27 patients; the company is targeting about 80 participants by the end of Q1 2027.
  • The program is supported by prior Phase 2 results that indicated a survival benefit, without reporting new performance details.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230800PRIMZONEFULLFEED9750800) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.